NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $100.08 -2.63 (-2.56%) As of 03:08 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Spyre Therapeutics Stock (NASDAQ:SYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyre Therapeutics alerts:Sign Up Key Stats Today's Range$99.11▼$102.3950-Day Range$66.62▼$102.7052-Week Range$14.51▼$105.09Volume267,585 shsAverage Volume1.10 million shsMarket Capitalization$8.80 billionP/E RatioN/ADividend YieldN/APrice Target$101.42Consensus RatingModerate Buy Company Overview Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications. Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts. The company utilizes advanced screening technologies and a modular engineering approach to optimize therapeutic candidates, streamline preclinical development and position its programs for clinical readiness. Based in the United States, Spyre Therapeutics operates a modern research and development facility that supports both in-house projects and external partnerships. Led by a management team experienced in biopharmaceutical innovation and development, the company is working to advance its lead programs into human trials and aims to bring new treatment options to patients with high-need cancers.AI Generated. May Contain Errors. Read More Spyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreSYRE MarketRank™: Spyre Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 1463rd out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingSpyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Spyre Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSpyre Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.86) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -48.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -48.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpyre Therapeutics has a P/B Ratio of 14.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Spyre Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.40% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 5.56.Change versus previous monthShort interest in Spyre Therapeutics has recently increased by 8.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentSpyre Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Spyre Therapeutics this week, compared to 4 articles on an average week.Search Interest4 people have searched for SYRE on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,741,101.00 in company stock.Percentage Held by Insiders15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Stock News HeadlinesSpyre Therapeutics Stock Dividends | NASDAQ:SYRE | BenzingaJuly 13, 2026 | benzinga.comJefferies Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)July 6, 2026 | theglobeandmail.comHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.July 22 at 1:00 AM | Stansberry Research (Ad)Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $658,050.00 in StockJuly 3, 2026 | insidertrades.comSpyre Therapeutics Announces Grants of Inducement AwardsJuly 2, 2026 | globenewswire.comSpyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting DataJune 30, 2026 | seekingalpha.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,306,950.00 in StockJune 27, 2026 | insidertrades.comMichael Thomas Henderson Sells 20,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 24, 2026 | insidertrades.comSee More Headlines SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $32.76 at the start of the year. Since then, SYRE shares have increased by 208.3% and is now trading at $101.0030. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) posted its earnings results on Tuesday, May, 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.08. When did Spyre Therapeutics IPO? Spyre Therapeutics (SYRE) raised $85 million in an initial public offering on Wednesday, April 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Who are Spyre Therapeutics' major shareholders? Spyre Therapeutics' top institutional shareholders include Handelsbanken Fonder AB (0.03%) and GAMMA Investing LLC. Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Jeffrey W Albers, Sheldon Sloan and Fairmount Funds Management Llc. View institutional ownership trends. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/05/2026Today7/22/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 SYRE's financial health is in the Green zone, according to TradeSmith. SYRE has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CIK1636282 Webwww.aeglea.com Phone512-942-2935Fax512-872-5121Employees73Year FoundedN/APrice Target and Rating Average Price Target for Spyre Therapeutics$101.42 High Price Target$135.00 Low Price Target$80.00 Potential Upside/Downside+1.3%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-42.88% Return on Assets-27.76% Debt Debt-to-Equity RatioN/A Current Ratio8.97 Quick Ratio8.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.21 per share Price / Book13.88Miscellaneous Outstanding Shares87,936,000Free Float74,139,000Market Cap$8.80 billion OptionableOptionable Beta3.02 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SYRE) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersMy next big call (under $1)People ask me one question more than any other: "Bryce, if you could only buy ONE coin right now... what would...Crypto 101 Media | SponsoredElon says “don’t save money.” Is he right?Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...Freedom Financial | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
